Xintela publishes positive preclinical results from equine study

Lund, Sweden, 3 February, 2020 - Xintela announces that the results from the company's stem cell study on horses has now been published in the respected scientific journal The American Journal of Sports Medicine. The publication demonstrates that the stem cell treatment is safe and that it has a significantly positive effect on both cartilage and bone health in a joint with osteoarthritis. The publication also presents and discusses various mechanisms that may be involved in this positive effect.

As previously reported, Xintela has conducted a preclinical study on horses with post-traumatic osteoarthritis to confirm that mesenchymal stem cells, selected and quality-assured with the company's marker technology, are safe and have the desired regenerative effect on a joint with osteoarthritis. The work was done in collaboration with Dr Lisa Fortier and her research team at Cornell University, Ithaca, New York, USA. The publication which is an extension of the previous study (read press release published on 4 January 2017: demonstrates that integrin a10-selected stem cells, injected into a joint after trauma, reduce the progression of osteoarthritis. The selected stem cells reduce both the degradation of the articular cartilage and the development of bone sclerosis, which are typical pathological osteoarthritis joint changes. Analysis of joint tissues and fluid further indicate that the stem cells have an immunomodulatory effect, which may contribute to the positive results. Importantly, in addition to positive efficacy, the study showed that the stem cell treatment is safe.

“There is a great need for a treatment that can regenerate the articular cartilage and restore the function of a joint with osteoarthritis. It is therefore very encouraging to publish the promising results that our stem cells have delivered in the equine osteoarthritis study.  These results are an important part of the preclinical documentation that support Xintela's next step - to conduct a clinical study on human patients with osteoarthritis”, says Xintela's CEO Evy Lundgren-Åkerlund.

The publication:
Integrin a10b1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model by Michelle L. Delco, Margaret Goodale, Jan F. Talts, Sarah L. Pownder, Matt Koff, Andrew D. Miller, Bridgette Nixon, Lawrence J. Bonassar, Evy Lundgren-Åkerlund and Lisa A. Fortier.
The American Journal of Sports Medicine, 2020, 1–12 DOI: 10.1177/0363546519899087.

To read the publication, visit:

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 3rd of February 2020.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].